{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:11:06Z","timestamp":1761394266601},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T00:00:00Z","timestamp":1356048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11940-012-0213-6","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T10:10:43Z","timestamp":1355998243000},"page":"224-239","source":"Crossref","is-referenced-by-count":27,"title":["Paraneoplastic Syndromes of the Neuromuscular Junction: Therapeutic Options in Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and Neuromyotonia"],"prefix":"10.1007","volume":"15","author":[{"given":"Agnes","family":"van Sonderen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan J. G. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"213_CR1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1196\/annals.1254.018","volume":"998","author":"JB Posner","year":"2003","unstructured":"Posner JB. Immunology of paraneoplastic syndromes: overview. Ann N Y Acad Sci. 2003;998:178\u201386.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"213_CR2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00415-010-5651-z","volume":"257","author":"I Casetta","year":"2010","unstructured":"Casetta I, Groppo E, De Gennaro R, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257(12):2015\u20139.","journal-title":"J Neurol"},{"key":"213_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"12","key":"213_CR4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1468-1331.2010.03089.x","volume":"17","author":"JB Andersen","year":"2010","unstructured":"Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010;17(12):1445\u201350.","journal-title":"Eur J Neurol"},{"issue":"5","key":"213_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390. This article provides a clear overview of the immunopathogenesis of myasthenia gravis and its subtypes.","journal-title":"Lancet Neurol"},{"issue":"10","key":"213_CR6","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304\u201311.","journal-title":"Brain"},{"issue":"4","key":"213_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445\u201351. This studies shows that a proportion of the AChR antibody-negative MG patients have autoantibodies to LRP4 and describes the involvement of these antibodies in the pathogenesis of MG.","journal-title":"Arch Neurol"},{"issue":"2","key":"213_CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418\u201322.","journal-title":"Ann Neurol"},{"key":"213_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1196\/annals.1254.025","volume":"998","author":"A Marx","year":"2003","unstructured":"Marx A, M\u00fcller-Hermelink HK, Str\u00f6bel P. The role of thymomas in the development of myasthenia gravis. Ann N Y Acad Sci. 2003;998:223\u201336.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"213_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36\u201340. A description of the demographic data, clinical course, response to treatment and long term outcome in a cohort of 110 MuSK-MG patients.","journal-title":"Muscle Nerve"},{"issue":"12","key":"213_CR11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098\u2013107. A detailed review of the pathogenesis and symptoms of LEMS and clarifying flow charts for the diagnostic work up and treatment of this rare disorder.","journal-title":"Lancet Neurol"},{"key":"213_CR12","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;973808. doi: 10.4061\/2011\/973808 .","DOI":"10.4061\/2011\/973808"},{"issue":"7","key":"213_CR13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902\u20138.","journal-title":"J Clin Oncol"},{"issue":"26","key":"213_CR14","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","volume":"26","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276\u201381.","journal-title":"J Clin Oncol"},{"issue":"1","key":"213_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","volume":"18","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19\u201327.","journal-title":"Eur J Neurol"},{"issue":"10","key":"213_CR16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.clinph.2006.03.008","volume":"117","author":"P Maddison","year":"2006","unstructured":"Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117(10):2118\u201327.","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"213_CR17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4103\/0028-3886.28110","volume":"54","author":"A Panagariya","year":"2006","unstructured":"Panagariya A, Kumar H, Mathew V, Sharma B. Neuromyotonia: clinical profile of twenty cases from northwest India. Neurol India. 2006;54(4):382\u20136.","journal-title":"Neurol India"},{"issue":"9","key":"213_CR18","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","volume":"133","author":"SR Irani","year":"2010","unstructured":"Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734\u201348. Interesting study identifying LGI1 and Caspr2 as the major targets of antibodies against the VGKC-complex. The article describes the differences in clinical features and risk of underlying tumour in patients with these antibodies.","journal-title":"Brain"},{"issue":"8","key":"213_CR19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","volume":"9","author":"M Lai","year":"2010","unstructured":"Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776\u201385.","journal-title":"Lancet Neurol"},{"issue":"2","key":"213_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","volume":"69","author":"E Lancaster","year":"2011","unstructured":"Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69(2):303\u201311. This study investigates the clinical manifestations and the role of Caspr2 antibodies in neuromyotonia and in encephalitis previously attributed to VGKC-antibodies.","journal-title":"Ann Neurol"},{"issue":"2","key":"213_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","volume":"72","author":"SR Irani","year":"2012","unstructured":"Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241\u201355.","journal-title":"Ann Neurol"},{"issue":"4","key":"213_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/CND.0b013e318246197d","volume":"13","author":"SS Rana","year":"2012","unstructured":"Rana SS, Ramanathan RS, Small G, Adamovich B. Paraneoplastic Isaacs' syndrome: a case series and review of the literature. J Clin Neuromuscul Dis. 2012;13(4):228\u201333.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"Pt 8","key":"213_CR23","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","volume":"125","author":"IK Hart","year":"2002","unstructured":"Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125(Pt 8):1887\u201395.","journal-title":"Brain"},{"key":"213_CR24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1254.022","volume":"998","author":"J Newsom-Davis","year":"2003","unstructured":"Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci. 2003;998:202\u201310.","journal-title":"Ann N Y Acad Sci"},{"issue":"17","key":"213_CR25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF01712058","volume":"43","author":"HG Mertens","year":"1965","unstructured":"Mertens HG, Zschocke S. Neuromyotonia. Klin Wochenschr. 1965;43(17):917\u201325.","journal-title":"Klin Wochenschr"},{"issue":"3","key":"213_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002826-198706000-00003","volume":"10","author":"C Vasilescu","year":"1987","unstructured":"Vasilescu C, Alexianu M, Dan A. Valproic acid in Isaacs-Mertens syndrome. Clin Neuropharmacol. 1987;10(3):215\u201324.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"213_CR27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi L, Mantegazza R. Treatment of myasthenia gravis, focus on pyridostigmine. Clin Drug Investig. 2011;31(10):691\u2013701.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"213_CR28","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978\u201380.","journal-title":"Neurology"},{"issue":"9","key":"213_CR29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","volume":"65","author":"Y Hatanaka","year":"2005","unstructured":"Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology. 2005;65(9):1508\u20139.","journal-title":"Neurology"},{"key":"213_CR30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","volume":"841","author":"RW Tim","year":"1998","unstructured":"Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrom (LEMS), clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci. 1998;841:823\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"213_CR31","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","volume":"7","author":"JJGM Verschuuren","year":"2006","unstructured":"Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myastenic syndrome. Expert Opin Pharmacother. 2006;7(10):1323\u201336.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"213_CR32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, Van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"213_CR33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","volume":"244","author":"R Beekman","year":"1997","unstructured":"Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244(2):112\u20138.","journal-title":"J Neurol"},{"key":"213_CR34","doi-asserted-by":"crossref","unstructured":"Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myastenic syndrome. Cochrane Database Syst Rev. 2011, 16;(2):CD003279. doi: 10.1002\/14651858.CD003279.pub3 .","DOI":"10.1002\/14651858.CD003279.pub3"},{"issue":"23","key":"213_CR35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-diaminopyridine in the treatment of Lambert-Eaton myastenic syndrome. N Engl J Med. 1989;321(23):1567\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"213_CR36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603\u20137.","journal-title":"Neurology"},{"issue":"5","key":"213_CR37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795\u2013800.","journal-title":"Muscle Nerve"},{"issue":"6","key":"213_CR38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/eci.10.57","volume":"6","author":"PW Wirtz","year":"2010","unstructured":"Wirtz PW, Titulaer MJ, Van Gerven JMA, Verschuuren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol. 2010;6(6):867\u201374.","journal-title":"Expert Rev Clin Immunol"},{"key":"213_CR39","doi-asserted-by":"crossref","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005, 18;(2):CD002828. doi: 10.1002\/14651858.CD002828.pub2 .","DOI":"10.1002\/14651858.CD002828.pub2"},{"issue":"3","key":"213_CR40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Branch Coslett H, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291\u20138.","journal-title":"Ann Neurol"},{"issue":"4","key":"213_CR41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251\u20135.","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"213_CR42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131\u20133.","journal-title":"J Neurol Sci"},{"issue":"24","key":"213_CR43","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","volume":"68","author":"M Benatar","year":"2007","unstructured":"Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;68(24):2144\u20139.","journal-title":"Neurology"},{"issue":"8","key":"213_CR44","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314\u201320.","journal-title":"J Neurol"},{"key":"213_CR45","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008, (1):CD002277. doi: 10.1002\/14651858.CD002277.pub3 .","DOI":"10.1002\/14651858.CD002277.pub3"},{"issue":"11","key":"213_CR46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Eduardo N, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837\u201341.","journal-title":"Neurology"},{"issue":"6","key":"213_CR47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41(6):789\u201396.","journal-title":"Ann Neurol"},{"issue":"12","key":"213_CR48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J R\u00f8nager","year":"2001","unstructured":"R\u00f8nager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967\u201373.","journal-title":"Artif Organs"},{"issue":"23","key":"213_CR49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"3","key":"213_CR50","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"PG Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678\u201383.","journal-title":"Neurology"},{"issue":"3","key":"213_CR51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0303-8467(00)00093-7","volume":"102","author":"G Alessi","year":"2000","unstructured":"Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg. 2000;102(3):173\u20135.","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"213_CR52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ncl.2010.03.024","volume":"28","author":"MP Merchut","year":"2010","unstructured":"Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin. 2010;28(4):941\u201359.","journal-title":"Neurol Clin"},{"issue":"5","key":"213_CR53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","volume":"46","author":"N Collongues","year":"2012","unstructured":"Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012;46(5):687\u201391.","journal-title":"Muscle Nerve"},{"issue":"2","key":"213_CR54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/CND.0b013e3181ff49f3","volume":"12","author":"H Ibrahim","year":"2010","unstructured":"Ibrahim H, Dimachkie MM, Shaibani A. A review: the use of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis. 2010;12(2):91\u2013102.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"213_CR55","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","volume":"16","author":"C Lebrun","year":"2009","unstructured":"Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246\u201350.","journal-title":"Eur J Neurol"},{"issue":"3","key":"213_CR56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189\u201393. A follow-up study of the long-term outcome of MG patients treated with rituximab, and a comparison of treatment response in AChR MG and MuSK MG.","journal-title":"Neurology"},{"issue":"6","key":"213_CR57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","volume":"82","author":"P Maddison","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"213_CR58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","volume":"4","author":"RJ Nowak","year":"2011","unstructured":"Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259\u201366.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"213_CR59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","volume":"82","author":"S Blum","year":"2011","unstructured":"Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(6):659\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"213_CR60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","volume":"40","author":"HL Pellkofer","year":"2009","unstructured":"Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve. 2009;40(2):305\u20138.","journal-title":"Muscle Nerve"},{"issue":"11","key":"213_CR61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","volume":"56","author":"P Gajdos","year":"1993","unstructured":"Myasthenia Gravis Clinical Study Group, Gajdos P, Elkharrat D, Chevret S, et al. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry. 1993;56(11):1157\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"213_CR62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","volume":"150","author":"MB Bromberg","year":"1997","unstructured":"Bromberg MB, Wald JJ, Forshew DA. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59\u201362.","journal-title":"J Neurol Sci"},{"issue":"6","key":"213_CR63","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Myasthenia Gravis Study Group, Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"key":"213_CR64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","volume":"255","author":"JW Chan","year":"2008","unstructured":"Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol. 2008;255:510\u20133.","journal-title":"J Neurol"},{"issue":"5","key":"213_CR65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593\u20138.","journal-title":"Muscle Nerve"},{"issue":"6","key":"213_CR66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"Muscle Study Group","year":"2008","unstructured":"Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394\u20139.","journal-title":"Neurology"},{"issue":"6","key":"213_CR67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136.","journal-title":"Neurology"},{"issue":"12","key":"213_CR68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719\u201324.","journal-title":"N Engl J Med"},{"key":"213_CR69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"213_CR70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254\u201363.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"213_CR71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","volume":"11","author":"CB Zhao","year":"2011","unstructured":"Zhao CB, Zhang X, Zhang H. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol. 2011;11(4):519\u201324.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"213_CR72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol. 2005;53(3):146\u201350.","journal-title":"Eur Neurol"},{"issue":"9","key":"213_CR73","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"213_CR74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"11","author":"JM Heckmann","year":"2011","unstructured":"Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.","journal-title":"BMC Neurol"},{"issue":"3","key":"213_CR75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","volume":"33","author":"PT Lin","year":"2006","unstructured":"Lin PT, Martin BA, Weinacker AB, So YT. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33(3):433\u20135.","journal-title":"Muscle Nerve"},{"issue":"5","key":"213_CR76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jnnp.2003.019232","volume":"75","author":"DE Gladstone","year":"2004","unstructured":"Gladstone DE, Brannagan 3rd TH, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75(5):789\u201391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"213_CR77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG Feo De","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31\u20136.","journal-title":"Muscle Nerve"},{"issue":"15","key":"213_CR78","first-page":"939","volume":"12","author":"P Gajdos","year":"1983","unstructured":"Gajdos P, Simon N, de Rohan-Chabot P, et al. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med. 1983;12(15):939\u201342.","journal-title":"Presse Med"},{"key":"213_CR79","first-page":"161","volume":"46","author":"A Kamel","year":"2009","unstructured":"Kamel A, Essa M. Effectiveness of prethymecthomy plasmapheresis on short-term outcome of non-thymomatous generalized myasthenia gravis. Egypt J Neurol Psychiatry Neurosurg. 2009;46:161\u20138.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"4","key":"213_CR80","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","volume":"34","author":"J Newsom-Davis","year":"1984","unstructured":"Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34(4):480\u20135.","journal-title":"Neurology"},{"issue":"8759","key":"213_CR81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0140-6736(91)90073-X","volume":"338","author":"S Sinha","year":"1991","unstructured":"Sinha S, Newsom-Davis J, Mills K, et al. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet. 1991;338(8759):75\u20137.","journal-title":"Lancet"},{"issue":"1\u20132","key":"213_CR82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-510X(00)00407-X","volume":"181","author":"GR Hayat","year":"2000","unstructured":"Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci. 2000;181(1\u20132):38\u201343.","journal-title":"J Neurol Sci"},{"issue":"5","key":"213_CR83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jca.21233","volume":"27","author":"EA Jaben","year":"2012","unstructured":"Jaben EA, Winters JL. Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher. 2012;27(5):267\u201373.","journal-title":"J Clin Apher"},{"issue":"1","key":"213_CR84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GS Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7\u201315.","journal-title":"Neurology"},{"issue":"3","key":"213_CR85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0404.2003.00209.x","volume":"109","author":"GR Guillermo","year":"2004","unstructured":"Guillermo GR, T\u00e9llez-Zenteno JF, Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand. 2004;109(3):217\u201321.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"213_CR86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","volume":"115","author":"HK Yuan","year":"2007","unstructured":"Yuan HK, Huang BS, Kung SY, Kao KP. The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases. Acta Neurol Scand. 2007;115(3):181\u20134.","journal-title":"Acta Neurol Scand"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-012-0213-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0213-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:59Z","timestamp":1559437019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-012-0213-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0213-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}